


CLAIMS

1. A compound of formula I



I

wherein

X is methylene, oxygen, sulphur or a NR⁷ group;

R¹ is a straight or branched C₁-C₈ alkyl or C₃-C₈ alkenylene or C₃-C₈ alkynylene chain, optionally substituted with CF₃, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C₁-C₄ alkyl, halogens, trifluoromethyl, hydroxy or C₁-C₄ alkoxy groups;

R², R³ are independently hydrogen, a C₁-C₃ alkyl chain, halogen, trifluoromethyl, hydroxy or C₁-C₄ alkoxy groups;

R⁴, R⁵, R⁶, R⁷ are independently hydrogen or C₁-C₆ alkyl;

and the pharmaceutically acceptable salts thereof.

2. Compounds of formula (I) according to claim 1, wherein X is oxygen, methylene, NH or NCH₃, R¹ is C₁-C₈ alkyl chain, optionally substituted with CF₃, phenyl or phenoxy group, where the aromatic ring in R¹ is optionally substituted by one or two halogen or methoxy or trifluoromethyl groups, R² and R³ are hydrogen, methyl, methoxy, fluorine, chlorine or bromine, R⁴, R⁵ and R⁶ are hydrogen or methyl.

3. A compound selected from the group consisting of:

2-(2-benzyloxy-benzylamino)-cyclopentane carboxylic acid amide;

2-(3-benzyloxy-benzylamino)-cyclopentane carboxylic acid amide;

2-(4-benzyloxy-benzylamino)-cyclopentane carboxylic acid amide;

5 2-[2-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

2-[3-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

10 *cis*-2-[3-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzylthio)-benzylamino]-cyclopentane carboxylic acid amide;

15 2-[4-(2-Fluoro-benzylamino)-benzylamino]-cyclopentane carboxylic acid amide;

2-[2-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-cyclopentane carboxylic acid amide;

20 2-[4-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-cyclopentane carboxylic acid amide;

2-[2-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-cyclopentane carboxylic acid amide;

25 (2-[4-(2-Fluoro-benzyloxy)-3-bromo-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-2-methoxy-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-3-methoxy-benzylamino]-cyclopentane
carboxylic acid amide;


2-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-cyclopentane
carboxylic acid amide;

5 *cis*-2-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-cyclopentane
carboxylic acid amide;

and all the stereoisomers and/or pharmaceutically acceptable salts thereof.

4. A process for the preparation of a compound of formula I, as defined in
claim 1, or a pharmaceutically acceptable salt thereof, the process comprising:


10 a) reaction of a compound of formula II



II

wherein R^1 , R^2 , R^3 and X are as defined above

15 with compounds of formula III, in the presence of a reducing agent




III

wherein R^4 , R^5 and R^6 are as defined previously thus obtaining a

20 compound of formula I; or

b) reaction of compounds of formula IV




IV

wherein X, R¹, R² and R³ are as defined above and Y is a halogen atom or a O-EWG group, where the EWG means an electron withdrawing group, like e.g. mesyl, tosyl or trifluoroacetyl groups, able to transform the oxygen which they are linked to, in a good leaving group

with compounds of formula III thus obtaining a compound of formula I; or

c) reacting of a compound of formula Ia



Ia

wherein R¹, R², R³, R⁵, R⁶ and X are as defined above, with compounds

of formula V or VI



V



VI

wherein Y and R⁴ are as defined above; and R⁸ is hydrogen or C₁-C₅ alkyl, thus obtaining a compound of the invention in which R⁴ is C₁-C₆ alkyl; and, if desired, converting a compound of the invention into another compound of the invention and/or, if desired, converting a compound of the invention into a pharmaceutically acceptable salt and/or, if desired, converting

a salt into a free compound and/or, if desired, separating a mixture of isomers of compounds of the invention into a single isomer.

5 5. A pharmaceutical composition containing a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof in admixture with a suitable carrier and/or diluent and optionally to other therapeutic agents.

6. The use of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament having sodium and/or calcium channel modulating activity for preventing,
10 alleviating and curing neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where sodium and/or calcium channels are involved in the pathological process.